Madrigal Pharmaceuticals, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:MDGL) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 114.65 M
Employee 915
Founded 2011
CEO Paul A. Friedman
Website www.madrigalpharma.com
Headquarter Delaware, United States
FIGI BBG000QS6NV8
Industry Biotechnology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

Price to earnings ratio

-34.99

Price to sales ratio

11.04

News

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Altimmune Catalysts: 2026 Data Readouts and Financing Risks

ALT Stock: What Pemvidutide Means for MASH, AUD and ALD

Is Altimmune a Buy Before Phase III MASH Starts in 2026?

United Therapeutics (UTHR) Up 5.7% Since Last Earnings Report: Can It Continue?

Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

ALT Pemvidutide Explained: What Makes It Different in MASH